TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE)
$32.22 0.66 (2.0913%)
Analysed TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) News Sources
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
09-07-2026
fool.com
Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar
10-07-2026
pharmaceutical-technology.com
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
12-07-2026
marketbeat.com
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study
12-07-2026
marketbeat.com
Teva (TEVA) Reports Promising Vitiligo Trial Results And Moves Anti IL 15 Drug Forward
13-07-2026
yahoo.com
Is JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?
13-07-2026
yahoo.com
Teva (TEVA) Stock Looks Discounted On Cash Flow Yet Fair On Earnings
13-07-2026
yahoo.com
Deckers Brands Announces Conference Call to Review First Quarter Fiscal 2027 Earnings Results
13-07-2026
yahoo.com
Teva Pharmaceutical Industries (TEVA) Could Be 21% Below Fair Value On Vitiligo Trial Progress
14-07-2026
yahoo.com
J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised
15-07-2026
yahoo.com
What is the current price of TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE)?
The current price of TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) is $32.22.
TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) absolute price change since previous trading day?
The absolute price change of TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) since the previous trading day is $0.66.
TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) percentage price change since previous trading day?
The percentage price change of TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) since the previous trading day is 2.0913%.
What is the most recent average sentiment score for TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE)?
The most recent average sentiment score for TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) is 65 out of 100.
What is the most recent average sentiment for TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE)?
The most recent sentiment for TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE) is .
SEC-8K** Filing Available For TEVA PHARMACEUTICAL-SP ADR (TEVA:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.